文献速递肿瘤 PET/CT

前列腺癌生化复发:[18F]PSMA-1007 PET/CT的初步结果

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.
PubMed 文献 · J Nucl Med · 2018-02-01

本研究纳入12例局部治疗后生化复发的前列腺癌患者,分别在注射18F-PSMA-1007后1小时和3小时行PET/CT扫描。结果显示9/12例(75%)检出病灶,注射后3小时病灶摄取较1小时显著增高(中位SUVmax 7.00 vs 11.34,P<0.001,n=76),50枚阳性淋巴结中44枚(88%)短径小于8 mm。作者结论认为18F-PSMA-1007 PET/CT在生化复发患者复发灶定位方面呈现高潜力。

要点

  • 12例生化复发患者中9例(75%)经18F-PSMA-1007 PET/CT检出病灶
  • 注射后3小时病灶摄取较1小时显著增高(中位SUVmax 7.00 vs 11.34,P<0.001)
  • 50枚阳性淋巴结中44枚(88%)短径小于8 mm

核心结论

  • 在这项先导研究中,18F-PSMA-1007 PET/CT在前列腺癌生化复发患者复发灶定位方面呈现高潜力。

研究设计与样本

  • 12例局部治疗后生化复发的患者接受18F-PSMA-1007 PET/CT扫描,分别在注射后1小时和3小时进行。

主要发现

  • 18F-PSMA-1007 PET/CT在9/12例患者(75%)中检出病灶。
  • 比较注射后1小时与3小时18F-PSMA-1007阳性病灶的示踪剂摄取,差异显著(中位SUVmax 7.00 vs 11.34;P<0.001;n=76)。
  • 50枚18F-PSMA-1007阳性淋巴结中44枚(88%)短轴直径小于8 mm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results:18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Giesel FL, Will L, Kesch C, et al. Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT. J Nucl Med. 2018. PMID: 29419475. doi:10.2967/jnumed.117.196329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。